The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | A | Alimentary tract and metabolism | |
| 2 | A07 | Antidiarrheals, intestinal antiinflammatory/antiinfective agents | |
| 3 | A07E | Intestinal antiinflammatory agents | |
| 4 | A07EC | Aminosalicylic acid and similar agents | |
| 5 | A07EC02 | Mesalazine |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 1.5 g |
| RECTAL - Rectal | 1.5 g |
| Active Ingredient | Description | |
|---|---|---|
| Mesalazine |
Mesalazine is an aminosalicylate. The mechanism of action of mesalazine is not fully understood, but appears to have a topical anti-inflammatory effect on the colonic epithelial cells. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase and lipoxygenase pathways, is increased in patients with chronic inflammatory bowel disease, and it is possible that mesalazine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ASACOLON Gastro-resistant tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
| ASACOLON Suppository | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
| MECOLZINE Gastro-resistant tablet | Web Search | MPI, EU: SmPC | |
| MECOLZINE Suppository | Web Search | MPI, EU: SmPC | |
| MESASAL Enteric-coated tablet | Pharmaceutical Benefits Scheme (AU) | MPI, EU: SmPC | |
| MEZAVANT XL Gastro-resistant, prolonged release tablets | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| PENTASA Prolonged release granules | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
| PENTASA Suppository | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| ROWASA Rectal suspension | FDA, National Drug Code (US) | MPI, US: SPL/Old | |
| SALOFALK Gastro-resistant tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
